Metabolite biomarkers of CKD progression in children
MR Denburg, Y Xu, AG Abraham… - Clinical Journal of the …, 2021 - journals.lww.com
Results Baseline characteristics were 391 (61%) male; median age 12 years; median eGFR
54 ml/min per 1.73 m 2; 448 (69%) nonglomerular diagnosis. Over a median follow-up of 4.8 …
54 ml/min per 1.73 m 2; 448 (69%) nonglomerular diagnosis. Over a median follow-up of 4.8 …
Metabolite Biomarkers of CKD Progression in Children.
MR Denburg, Y Xu, AG Abraham… - Clin J Am …, 2021 - scholarlyexchange.childrensmercy …
"Metabolite Biomarkers of CKD Progression in Children." by Michelle R. Denburg, Yunwen Xu
et al. Home Search Browse Collections My Account About DC Network Digital Commons …
et al. Home Search Browse Collections My Account About DC Network Digital Commons …
Metabolite biomarkers of ckd progression in children
MR Denburg, Y Xu, AG Abraham… - Clinical Journal of …, 2021 - ohiostate.elsevierpure.com
Background and objectivesMetabolomics facilitates the discovery of biomarkers and
potential therapeutic targets for CKD progression. Design, setting, participants, & …
potential therapeutic targets for CKD progression. Design, setting, participants, & …
Metabolite biomarkers of ckd progression in children
MR Denburg, Y Xu, AG Abraham… - Clinical Journal of …, 2021 - pure.johnshopkins.edu
Background and objectivesMetabolomics facilitates the discovery of biomarkers and
potential therapeutic targets for CKD progression. Design, setting, participants, & …
potential therapeutic targets for CKD progression. Design, setting, participants, & …
Metabolite biomarkers of ckd progression in children
MR Denburg, Y Xu… - … Journal of the …, 2021 - utsouthwestern.elsevierpure.com
Background and objectivesMetabolomics facilitates the discovery of biomarkers and
potential therapeutic targets for CKD progression. Design, setting, participants, & …
potential therapeutic targets for CKD progression. Design, setting, participants, & …
[HTML][HTML] Metabolite biomarkers of ckd progression in children
MR Denburg, Y Xu, AG Abraham… - Clinical Journal of the …, 2021 - experts.umn.edu
BACKGROUND AND OBJECTIVES: Metabolomics facilitates the discovery of biomarkers
and potential therapeutic targets for CKD progression. DESIGN, SETTING, PARTICIPANTS …
and potential therapeutic targets for CKD progression. DESIGN, SETTING, PARTICIPANTS …
Metabolite biomarkers of ckd progression in children
MR Denburg, Y Xu, AG Abraham… - Clinical Journal of …, 2021 - scholars.uthscsa.edu
Background and objectivesMetabolomics facilitates the discovery of biomarkers and
potential therapeutic targets for CKD progression. Design, setting, participants, & …
potential therapeutic targets for CKD progression. Design, setting, participants, & …
[HTML][HTML] Metabolite Biomarkers of CKD Progression in Children
MR Denburg, Y Xu, AG Abraham, J Coresh… - Clinical Journal of the …, 2021 - ncbi.nlm.nih.gov
Metabolite Biomarkers of CKD Progression in Children - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content …
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content …
Metabolite Biomarkers of CKD Progression in Children
MR Denburg, Y Xu, AG Abraham… - Clinical journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and objectives Metabolomics facilitates the discovery of biomarkers and
potential therapeutic targets for CKD progression. Design, setting, participants, & …
potential therapeutic targets for CKD progression. Design, setting, participants, & …
Metabolite Biomarkers of CKD Progression in Children.
MR Denburg, Y Xu, AG Abraham, J Coresh… - Clinical Journal of the …, 2021 - europepmc.org
Results Baseline characteristics were 391 (61%) male; median age 12 years; median eGFR
54 ml/min per 1.73 m 2; 448 (69%) nonglomerular diagnosis. Over a median follow-up of 4.8 …
54 ml/min per 1.73 m 2; 448 (69%) nonglomerular diagnosis. Over a median follow-up of 4.8 …